Smith & Nephew SNATS Net Cash Flow 2010-2025 | SNN

Smith & Nephew SNATS net cash flow for the twelve months ending June 30, 2025 was $357M, a 113.99% decline year-over-year.

  • Smith & Nephew SNATS annual net cash flow for 2024 was $0.317B, a 820.45% decline from 2023.
  • Smith & Nephew SNATS annual net cash flow for 2023 was $-0.044B, a 95.32% decline from 2022.
  • Smith & Nephew SNATS annual net cash flow for 2022 was $-0.941B, a 101.93% increase from 2021.

Smith & Nephew SNATS Net Cash Flow 2010-2025 | SNN

  • Smith & Nephew SNATS annual net cash flow for 2024 was $0.317B, a 820.45% decline from 2023.
  • Smith & Nephew SNATS annual net cash flow for 2023 was $-0.044B, a 95.32% decline from 2022.
  • Smith & Nephew SNATS annual net cash flow for 2022 was $-0.941B, a 101.93% increase from 2021.
Related Stocks
Company NameMarket
Cap
Abbott Laboratories (ABT)$229.5B
Boston Scientific (BSX)$155.7B
Stryker (SYK)$149.4B
EssilorLuxottica (ESLOY)$144.2B
Medtronic (MDT)$118B
Lonza Group Ag (LZAGY)$49.7B
Haleon (HLN)$43.4B
ResMed (RMD)$41.8B
GE HealthCare Technologies (GEHC)$34.1B
Agilent Technologies (A)$33.8B
Koninklijke Philips (PHG)$26.6B
Terumo (TRUMY)$26.2B
Insulet (PODD)$23.2B
Zimmer Biomet Holdings (ZBH)$21.3B
Baxter (BAX)$12.6B
Sunny Optical Technology (SNPTF)$10.8B
Demant (WILYY)$8.1B
Bio-Rad Laboratories (BIO)$8B
Lantheus Holdings (LNTH)$3.8B
Envista Holdings (NVST)$3.5B
Shandong Weigao Medical Polymer (SHWGF)$3.5B
Perrigo (PRGO)$3.3B
Prestige Consumer Healthcare (PBH)$3.2B
ICU Medical (ICUI)$3.1B
Haemonetics (HAE)$2.7B
LeMaitre Vascular (LMAT)$2.2B
Acuren (TIC)$2.1B
Curaleaf Holdings (CURLF)$2B
AtriCure (ATRC)$1.9B
QuidelOrtho (QDEL)$1.9B